Recent

% | $
Quotes you view appear here for quick access.

iShares Cohen & Steers REIT Message Board

dowmoneyus 12 posts  |  Last Activity: Mar 18, 2015 9:19 PM Member since: Feb 25, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Big Jump tomorrow?

    by tallyparty Mar 18, 2015 8:26 PM
    dowmoneyus dowmoneyus Mar 18, 2015 9:19 PM Flag

    More big news for Ovarian Cancer product early next week. So no reason to sell this time when more upside coming in just days with Cantrixil Data to be Presented at Two Major Conferences. Cantrixil efficacy in ovarian cancer stem cells,

    Sentiment: Hold

  • How do I know? I have read an analyst report that said because the July 29, 2014
    FDA Accepts for Review Adamis’ New Drug Application for Its Epinephrine Pre-Filled Syringe.

    Its meant for institutional supply only like hospitals and other major medical facilities! That is why its a slam dunk 99.999% approval chance.

    Sentiment: Strong Buy

  • The stock is only at $24.89 ! The premium is ridiculous unless its heading much higher than $40 in April, otherwise its useless to buy calls.
    CLDN Apr 2015 25.000 call (CLDN150417C00025000) -OPR
    $5.30 Up (20.00%) 8:46PM EDT

    Sentiment: Hold

  • Then you would not have to worry about offering like here because they Have $0 cash.

    Sentiment: Strong Sell

  • Both are exactly the same Market Cap, no need to gamble though. Just get in both stocks and you cover all the bases.

    Sentiment: Strong Buy

  • Reply to

    Any Articles about Cempra’s predicted earnings?

    by eyeisman Feb 23, 2015 8:22 PM
    dowmoneyus dowmoneyus Feb 23, 2015 9:30 PM Flag

    $16 million funding may have been forgotten. CHAPEL HILL, N.C., Nov. 19, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it has received authorization under its existing contract for the next phase of its contract with the Biomedical Advanced Research and Development Authority (BARDA) that will provide funding of $16.0 million for two clinical studies of solithromycin. Pediatric patients from newborn to age 17 years who are enrolled in the study may receive intravenous, oral suspension or oral capsule formulations of solithromycin, an investigational, fourth generation macrolide antibiotic. In a recently completed Phase 1a study conducted in pediatric patients age 12 to 17 years, solithromycin oral capsules were well tolerated and demonstrated a pharmacokinetic profile similar to that seen in adults.

    Sentiment: Strong Buy

  • Revenue of 109.57B, probably will have a SUV/Crossover vehicle ready before TSLA and Ferrari IPO soon will put eyes on it that will wake up some folks at the 10 forward PE of FCAU.

    Sentiment: Strong Buy

  • Have no fear guys, short at will because an earnings beat is priced in. They would have to really crush it to go up.

    Sentiment: Strong Sell

  • So shorts have nothing to fear on Friday, if anything happens it would be on a Monday.
    Just the way it always has been.

    But does anyone know if the 'Street' has any names on who would be bidding for PVA or the others on the list?

  • 90/4= 22.5 x better profit ratio then Amzn, so in comparison if Amzn shares can go up $38/shr on its earnings, Aapl should have gone up 22.5X higher then $38/shr for equal profit multiple gains.

    Sentiment: Strong Sell

  • $16.0 Million Will be Provided to Cover the Cost of the Study and Other Activities Specified in the Contract

    Phase 1b and Phase 2/3 Studies Will Test Intravenous, Oral Capsule and Oral Suspension Formulations of Solithromycin in Pediatric Patients From Newborn to 17 Years of Age

    Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services (Contract No. HHS0100201300009C) for the evaluation and development of solithromycin for the treatment of bacterial infections in pediatric populations and infections caused by bioterror threat pathogens, specifically anthrax and tularemia. The BARDA agreement is a cost plus fixed fee development contract with a base performance segment plus four option segments. If all four option segments are requested, the total value of the agreement would be approximately $58.6 million with a period of service to 2018.

    About Cempra, Inc.

    Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) is in Phase 3 clinical development for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin also recently entered a Phase 3 clinical trial for uncomplicated bacterial urethritis caused by Neisseria gonorrhoeae and chlamydia. Taksta™ (CEM-102) is Cempra's second product candidate, which is being developed for chronic oral treatment of staphylococcal infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders.

    Sentiment: Strong Buy

  • The stock symbol is CEMP, they have multibillion drug called Soli that passed with flying colors its first round of phase 3 results and set for blastoff with second set of phase 3 results in April. The share structure is the same as Kite with $200 million in cash when you include the $138M share offering which was completed last week. CEMP is going to $75 either with you or without you, its your choice.

    Sentiment: Strong Buy

ICF
98.28-0.43(-0.44%)Apr 17 4:00 PMEDT